BioAge Labs, Inc. (NASDAQ:BIOA) Stock Now Rated “Moderate Buy” by Sell-Side Analysts

Shares of BioAge Labs, Inc. (NASDAQ:BIOA) have earned a consensus rating of “Moderate Buy” from the seven research firms that are presently covering the company, MarketBeat.com reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 1 year target price among brokerages that have updated their coverage on the stock in the last year is $36.57.

Several equities research analysts have issued reports on the company. Wall Street Zen upgraded BioAge Labs from a “strong sell” rating to a “sell” rating in a report on Sunday, September 13th. Roth Capital reissued a “buy” rating and set a $25.00 price objective on shares of BioAge Labs in a report on Wednesday, September 9th. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAge Labs in a research note on Tuesday, July 21st. Jefferies Financial Group set a $21.00 target price on BioAge Labs in a report on Friday, July 31st. Finally, Needham & Company LLC dropped their price target on BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research report on Friday, July 31st.

BioAge Labs Stock Down 0.5%

Shares of BIOA opened at $6.26 on Thursday. BioAge Labs has a fifty-two week low of $5.04 and a fifty-two week high of $25.95. The company’s fifty day moving average is $9.39 and its two-hundred day moving average is $15.72. The firm has a market cap of $287.33 million, a PE ratio of -2.63 and a beta of 1.08.

BioAge Labs (NASDAQ:BIOA) last issued its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.65) by $0.07. The firm had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. As a group, equities research analysts anticipate that BioAge Labs will post -2.45 earnings per share for the current year.

Institutional Investors Weigh In On BioAge Labs

A number of hedge funds have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in shares of BioAge Labs in the 2nd quarter worth about $84,000. State of Wyoming acquired a new position in shares of BioAge Labs during the second quarter worth approximately $154,000. The Manufacturers Life Insurance Company bought a new position in BioAge Labs in the 2nd quarter worth approximately $234,000. Bank of Nova Scotia acquired a new stake in BioAge Labs in the 1st quarter valued at approximately $180,000. Finally, Engineers Gate Manager LP bought a new stake in BioAge Labs during the 2nd quarter valued at $344,000.

BioAge Labs Company Profile

BioAge Labs, Inc is a clinical-stage biotechnology company focused on developing medicines for diseases associated with aging. The company uses human longevity data, machine learning and biology research to identify therapeutic targets and develop treatments intended to address the biological drivers of aging and age-related decline.

BioAge’s pipeline has included azelaprag, formerly known as BGE-105, an investigational small-molecule agonist of the apelin receptor. The company has evaluated azelaprag in clinical studies involving muscle function and has also investigated its potential use in combination with incretin-based medicines for obesity.